A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial

Russell J. Schilder, John A. Blessing, Mark S. Shahin, David S. Miller, Krishnansu Sujata Tewari, Carolyn Y. Muller, David P. Warshal, Scott McMeekin, Jacob Rotmensch

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A gynecologic oncology group trial'. Together they form a unique fingerprint.